Orphan status in Europe for Kiadis' ATIR

Netherlands-based Kiadis Pharma says that its lead product, ATIR, has been granted orphan drug designation by the European Medicines Agency (EMEA) for the prevention of acute Graft-versus-Host Disease after an allogeneic bone marrow transplantation.

"Following the orphan drug designation granted by the [US Food and Drug Administration] for our lead product ATIR, this is another important milestone in the development of ATIR as a novel approach which may enable a safe and potentially life-saving mismatched bone marrow transplantation as a treatment option for end-stage blood cancer patients," says Manja Bouman, chief executive of Kiadis.